|Videos|January 28, 2022
Next-level Diagnosis and Compliance
Panelists provide pearls on how to make a smarter diagnosis, tailor treatment plans to patients’ lifestyles and preferences, and motivate pediatric patients to adhere to their treatment plan.
Advertisement
Advertisement
Related to this article
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5